California drug delivery company NanoSmart Pharmaceuticals has hooked up with the University of California Los Angeles (UCLA) to develop targeted drugs for cancer and other serious life-threatening diseases. NanoSmart's delivery system uses a combination of autoimmune antibodies and liposomes to target tumors and deliver FDA-approved cancer drugs. The technique has a number of advantages--it cuts the side effects of drugs that can be toxic, and reduces development time by using drugs already on the market and with a history of safety and efficacy. This follows an agreement signed in November 2011 with the Children's Hospital Los Angeles to use its drug delivery technology for drugs against a form of childhood cancer called Ewing's sarcoma. Press release